Browse all 652 ETFs by category, no search needed
Global 184
US market 64
Country 92
Core UCITS 16
Sector 103
Style & factor 111
Theme 45
Dividend 37
SPDR® S&P Biotech ETF (XBI)
Look-through valuation · Sector · Expense ratio 0.35 % · ISIN US78464A8707
Price history (since 2006)
Monthly close since 2006. Price shows performance, the valuation verdict is in the look-through above.
Top holdings
| Holding | Weight | vs fair value | Quality |
|---|---|---|---|
| Twist Bioscience Corp TWST | 1.7 % | n/a | n/a |
| Oruka Therapeutics, Inc. ORKA | 1.5 % | n/a | n/a |
| Apogee Therapeutics, Inc. Common Stock APGE | 1.5 % | n/a | n/a |
| Praxis Precision Medicines Inc PRAX | 1.5 % | n/a | n/a |
| Halozyme Therapeutics Inc HALO | 1.4 % | −42.3 % | 79 |
| Natera Inc NTRA | 1.4 % | −95.0 % | 37 |
| Insmed Inc INSM | 1.4 % | n/a | n/a |
| Revolution Medicines Inc RVMD | 1.3 % | n/a | n/a |
| Dianthus Therapeutics Inc. DNTH | 1.3 % | n/a | n/a |
| CG Oncology, Inc. Common stock CGON | 1.3 % | n/a | n/a |
| Protagonist Therapeutics Inc PTGX | 1.3 % | −97.4 % | 41 |
| Kymera Therapeutics Inc KYMR | 1.3 % | n/a | n/a |
| Erasca Inc ERAS | 1.3 % | n/a | n/a |
| Spyre Therapeutics Inc. SYRE | 1.3 % | n/a | n/a |
| Regeneron Pharmaceuticals Inc REGN | 1.3 % | −25.5 % | 72 |
| Moderna Inc MRNA | 1.2 % | −79.9 % | 45 |
| Rhythm Pharmaceuticals Inc RYTM | 1.2 % | n/a | n/a |
| Vaxcyte Inc PCVX | 1.2 % | n/a | n/a |
| Travere Therapeutics Inc TVTX | 1.2 % | −96.2 % | 35 |
| Relay Therapeutics Inc RLAY | 1.2 % | n/a | n/a |
| Arrowhead Pharmaceuticals Inc ARWR | 1.2 % | −89.4 % | 51 |
| BridgeBio Pharma Inc BBIO | 1.2 % | n/a | n/a |
| Roivant Sciences Ltd ROIV | 1.2 % | n/a | n/a |
| Biomarin Pharmaceutical Inc BMRN | 1.2 % | −43.5 % | 67 |
| Cogent Biosciences Inc UMRX | 1.2 % | n/a | n/a |
Fair value and quality per position come from the same valuation as our stock pages. Showing the 25 largest of 50 disclosed positions. "n/a" means the position is not (yet) in our stock universe and does not enter the average.
The 10 most cheaply valued ETFs
Measured against the look-through fair value of the holdings (sufficiently covered funds only). Green means below fair value, red above. Not financial advice.
- 1 CHIU Global X MSCI China Utilities ETF +71.9 % below FV
- 2 FXI iShares China Large-Cap ETF +53.7 % below FV
- 3 CHIQ Global X MSCI China Consumer Disc ETF +48.5 % below FV
- 4 FLCH Franklin FTSE China ETF +36.0 % below FV
- 5 KWEB KraneShares CSI China Internet ETF +33.5 % below FV
- 6 FCFY First Trust S&P 500 Diversified Free Cash Flow ETF +32.5 % below FV
- 7 MCHI iShares MSCI China ETF +28.0 % below FV
- 8 ITB iShares U.S. Home Construction ETF +13.7 % below FV
- 9 C003 Amundi Index Solutions - Amundi DivDAX I UCITS ETF EUR Distributing +12.7 % below FV
- 10 TAN Invesco Solar ETF +10.8 % below FV
How we value this ETF
An ETF has no fair value of its own like a single stock. We build it bottom up: every holding has a fair value and a quality score on our pages. Weighted by portfolio share, that gives SPDR® S&P Biotech ETF an average of how cheap or expensive its companies currently sit versus fair value, and how high their average quality is.
As of: Aug 14, 2026
The look-through is a computed summary of public fundamentals and is no substitute for your own research.